Design and implementation of a Pacific intervention to increase uptake of urate-lowering therapy for gout: a study protocol
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1475-9276
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Design and implementation of a Pacific intervention to increase uptake of urate-lowering therapy for gout: a study protocol ; volume:20 ; number:1 ; day:23 ; month:12 ; year:2021 ; pages:1-7 ; date:12.2021
International journal for equity in health ; 20, Heft 1 (23.12.2021), 1-7, 12.2021
- Klassifikation
-
Soziale Probleme, Sozialdienste, Versicherungen
- Urheber
-
Ofanoa, Malakai
Ofanoa, Samuela Malakai
Heather, Maryann
Tu’akoi, Siobhan
Lutui, Hinamaha
Dalbeth, Nicola
Grey, Corina
Werf, Bert van der
Goodyear-Smith, Felicity
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12939-021-01601-4
- URN
-
urn:nbn:de:101:1-2022041619493238122231
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:20 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Ofanoa, Malakai
- Ofanoa, Samuela Malakai
- Heather, Maryann
- Tu’akoi, Siobhan
- Lutui, Hinamaha
- Dalbeth, Nicola
- Grey, Corina
- Werf, Bert van der
- Goodyear-Smith, Felicity
- SpringerLink (Online service)
Ähnliche Objekte (12)
Variation in serum urate levels in the absence of gout and urate lowering therapy
Adherence with urate-lowering therapies for the treatment of gout
Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation
Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare
Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study
Urate lowering therapy in patients starting hemodialysis limit gout flares occurrence: ten years retrospective study
Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase
Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment
High Rate of Adherence to Urate-Lowering Treatment in Patients with Gout: Who’s to Blame?
The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age
Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout
Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study
Variation in serum urate levels in the absence of gout and urate lowering therapy
Adherence with urate-lowering therapies for the treatment of gout
Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation
Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare
Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study
Urate lowering therapy in patients starting hemodialysis limit gout flares occurrence: ten years retrospective study
Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase
Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment
High Rate of Adherence to Urate-Lowering Treatment in Patients with Gout: Who’s to Blame?
The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age
Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout
Facilitators and barriers to adherence to urate-lowering therapy in African-Americans with gout: a qualitative study
Variation in serum urate levels in the absence of gout and urate lowering therapy
Adherence with urate-lowering therapies for the treatment of gout
Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation
Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare
Gout prevalence and predictors of urate-lowering therapy use: results from a population-based study
Urate lowering therapy in patients starting hemodialysis limit gout flares occurrence: ten years retrospective study
Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase
Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment
High Rate of Adherence to Urate-Lowering Treatment in Patients with Gout: Who’s to Blame?
The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age
Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout